Clinical Trial Update: A 16 Week Study to Evaluate the Effect on Insulin Sensitivity of Valsartan (320 mg) and Hydrochlorothiazide (25 mg) Combined and Alone, in Patients With Metabolic Syndrome [Phase 4]

View source ↗

Summary

This notice reports the completion of a Phase 4 trial evaluating the effect on insulin sensitivity of valsartan 320 mg and hydrochlorothiazide 25 mg, given both…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension
• Metabolic Syndrome
• Prehypertension

Drugs mentioned

• HYDROCHLOROTHIAZIDE (hydrochlorothiazide)
• VALSARTAN (Valsartan)

Snippet

Sponsor: Novartis | Conditions: METABOLIC SYNDROME, HYPERTENSION | Phase 4 | Status: COMPLETED